<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01868594</url>
  </required_header>
  <id_info>
    <org_study_id>MMH-SU-003</org_study_id>
    <nct_id>NCT01868594</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type I Diabetes Mellitus</brief_title>
  <official_title>Multicentre Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type I Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Materia Medica Holding</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Materia Medica Holding</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is:

        -  to assess clinical efficacy of Subetta in the combined treatment of type I diabetes
           mellitus;

        -  to assess safety of Subetta in the combined treatment of type I diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with type I diabetes mellitus are included in the trial. It is concerned those
      patients, who by the time of the trial receive basal bolus insulin therapy of type I diabetes
      mellitus, including basal insulin (using long acting medications) and prandial insulin (short
      and ultra short acting medications), and with poor glycemic control (HbA1c=7.0-10.0%). For
      patients, which will be included in the trial (mainly middle aged patients without severe
      complications of diabetes), HbA1c&gt;7.0% is the marker showing that optimal individual goal of
      glycemic control is not achieved.

      HbA1c, fasting plasma glucose, microalbuminuria, estimated glomerular filtration rate,
      ophthalmoscopy, blood pressure measurement, patient self-monitoring of blood glucose,
      frequency of hypoglycemia, endocrinologist examination were performed within screening
      period. Patients without severe diabetes complications are randomized in 2 groups.

      If a patient meets inclusion criteria and does not show exclusion criteria he/she is
      randomized in one of 2 groups: Group 1 - patients receiving standard type I diabetes mellitus
      therapy + Subetta at a dose of 1 tablet 4 times a day; Group 2 - the group receiving standard
      type I diabetes mellitus therapy + Placebo under the regimen used for Subetta. The invented
      names of the drugs containing basal and prandial (meal) insulin should be unchanged for each
      patient during the whole trial.

      All patients will receive glucometers and the appropriate glucose test strips, so they could
      self monitor blood glucose and register this data in their diaries.

      The trial duration is 38 weeks; the main stages of the trial are conducted during screening,
      then in 4 weeks (Visit 2), in 12 weeks (Visit 3), in 24 weeks (Visit 4) and in 36 weeks
      (Visit 5). In 1 week after randomization and the onset of the trial therapy and between the
      visits to the study site (on weeks 8±1, 18±1 and 30±1) an investigator collects data on
      patient's health and complaints (phone visits) to decide whether it is necessary to arrange
      unplanned visit to the site.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 7, 2013</start_date>
  <completion_date type="Actual">July 10, 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the Mean Value of HbA1c</measure>
    <time_frame>baseline and 12, 24 and 36 weeks of the treatment</time_frame>
    <description>The HbA1C test was performed using a method that is certified by the National Glycohemoglobin Standardization Program (NGSP) (www.ngsp.org) and standardized or traceable to the Diabetes Control and Complications Trial (DCCT) reference assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Plasma Glucose (Based on the Data of Biochemical Analysis)</measure>
    <time_frame>baseline and 4, 12, 24 and 36 weeks of the treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Average Daily Blood Glucose From a 7-point Patient Self-monitoring of Blood Glucose (SMBG)</measure>
    <time_frame>baseline and 4, 8, 12, 18, 24, 30 and 36 weeks of the treatment</time_frame>
    <description>A 7-point patient self-monitoring of blood glucose (SMBG):
three measurements of blood glucose before the meal; three measurements of postprandial blood glucose (1-2 h after the start of the meal) and one measurement at 3:00 a.m.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Lipids (Concentrations of Plasma Total Cholesterol, HDL Cholesterol, LDL Cholesterol and Triglycerides)</measure>
    <time_frame>baseline and 12, 24 and 36 weeks of the treatment</time_frame>
    <description>Blood samples (for measurement of fasting plasma glucose, concentrations of plasma total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides) are taken under standard conditions: after night break in food taking (at least 12 hours) and prior to administering of insulin morning dose (prandial), prior to any morning medicines intake (including the study drug and permitted concomitant therapy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Dosage of Insulin (Basal, Prandial and Total Daily Dose Insulin Measured in IU)</measure>
    <time_frame>baseline and 36 weeks of the treatment</time_frame>
    <description>Insulin dose should be corrected by a patient on a daily basis taking into consideration data on blood glucose self- monitoring during a day and amount of food carbohydrates. Physician can correct insulin dose based on the same data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Dosage of Total Insulin Measured in IU/kg of Body Weight</measure>
    <time_frame>baseline and 36 weeks of the treatment</time_frame>
    <description>Insulin dose should be corrected by a patient on a daily basis taking into consideration data on blood glucose self- monitoring during a day and amount of food carbohydrates. Physician can correct insulin dose based on the same data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction of Diabetes Treatment Based on Diabetes Treatment Satisfaction Questionnaire Data</measure>
    <time_frame>36 weeks of the treatment</time_frame>
    <description>The Diabetes Treatment Satisfaction Questionnaire allows to assess the degree of satisfaction with treatment for diabetes and its complications - retinopathy and nephropathy, how patients' satisfaction and perceived hyper- and hypoglycemia have changed compared to the initial period (before the treatment).
The Diabetes Treatment Satisfaction Questionnaire contains six items scored on 7-point scales from +3 (equals &quot;very satisfied&quot;) to -3 (equals &quot;very dissatisfied&quot;), with 0 (equals &quot;no change&quot;). These are summed to produce a total Treatment Satisfaction score. Two questions concerning &quot;Perceived Hyperglycaemia&quot; and &quot;Perceived Hypoglycaemia&quot; respectively, are calculated separately. According to these two items, low scores represent good perceived blood glucose control (+3 means &quot;most of the time&quot; of Hyperglycaemia or Hypoglycaemia whereas -3 means &quot;none of the time&quot; of Hyperglycaemia or Hypoglycaemia).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Type I Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Subetta group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with poor glycemic control (HbA1c=7.0-10.0%) in basal-bolus insulin regimen with a stable basal insulin dose (permissible fluctuations are ±10%) during the previous 3 months are included</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients with poor glycemic control (HbA1c=7.0-10.0%) in basal-bolus insulin regimen with a stable basal insulin dose (permissible fluctuations are ±10%) during the previous 3 months are included.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subetta</intervention_name>
    <description>Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.
Standard therapy of type I diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.
Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime).</description>
    <arm_group_label>Subetta group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type I diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.
Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime).</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed type I diabetes mellitus (according to WHO criteria, 1999 - 2006).

          2. Disease duration no less than 6 months.

          3. Patient's age from 18 to 65 years inclusive.

          4. Level of glycosylated hemoglobin 7.0- 10.0 %.

          5. Glomerular filtration rate ≥ 60 ml/ min/1.73m^2.

          6. Stable dose of basal insulin for the last 3 months. (Permissible fluctuations are
             ±10%.)

          7. Usage of contraceptive methods by both gender patients of reproductive age during the
             trial and within 30 days after ending the participation in the trial.

          8. Availability of signed patient information sheet (Informed Consent form) for
             participation in the clinical trial.

        Exclusion Criteria:

          1. Acute diabetes mellitus complications for 3 months prior to inclusion in the trial
             (diabetic ketoacidosis, hyperosmolar hyperglycemic state, lacticemia, severe
             hypoglycemia and hypoglycemic coma).

          2. Diabetic retinopathy, preproliferative, proliferative or terminal stages (based on the
             results of oculist examination during screening period or 6 months prior to the
             trial).

          3. Diabetic nephropathy, proteinuria stage, chronic kidney disease on 3, 4 or 5 stage.

          4. Diabetic microangiopathy:

               -  ishemic heart disease (medical history of a sudden coronary death with successful
                  reanimation, medical history of myocardial infarction, stable exertional angina
                  III or IV FC; unstable angina; post-infarction cardiosclerosis; chronic heart
                  failure III or IV FC);

               -  cerebrovascular diseases (medical history of acute cerebrovascular accident;
                  progressive vascular leukoencephalopathy; vascular dementia);

               -  chronic obliterative peripheral vascular diseases (clinically significant);

               -  diabetic neuroosteoarthropathy;

               -  diabetic foot (clinically significant).

          5. Heart rhythm disorder:

               -  II-III atrioventricular block;

               -  sick sinus syndrome;

               -  long QT interval syndrome;

               -  complete left bundle branch block;

               -  block of 2/3 bundle branches;

               -  WPW syndrome;

               -  ventricular arrhythmia of III grade according Laun-Wolf;

               -  paroxysmal supraventricular tachycardia;

               -  paroxysmal/recurrent ventricular tachycardia;

               -  atrial flutter and fibrillation;

               -  ventricular flutter and fibrillation;

               -  heart pacemaker implant.

          6. Uncontrolled arterial hypertension characterized by the following blood tension
             values: systolic blood pressure over 160 mm Hg and/or diastolic blood pressure over
             100 mm Hg.

          7. Severe concomitant pathology including clinically significant cardiovascular diseases
             of III - IV functional class (according to New York Heart Association classification,
             1964), nervous and endocrine system diseases, including morbid obesity (body mass
             index≥40.0 kg/m2), renal insufficiency, liver failure.

          8. Medical history of pancreatectomy or transplantation of pancreatic/islet cells.

          9. Medical history of renal transplantation.

         10. Malignant neoplasms/suspected malignant neoplasms.

         11. Exacerbations or decompensation of chronic diseases affecting a patient's ability to
             participate in the clinical trial.

         12. Level of fasting triglycerides &gt;5.64 mmol/L.

         13. Medical history of bariatric surgical operations.

         14. Medical history of polyvalent allergy.

         15. Allergy/ intolerance to any of the components of medications used in the treatment.

         16. Intake of medicines listed in the section &quot;Prohibited concomitant treatment&quot; for 3
             months prior to the inclusion in the trial.

         17. Pregnancy, breast-feeding.

         18. Drug addiction, alcohol usage in the amount exceeding 2 units of alcohol per day.

         19. Mental disorders of a patient.

         20. Night work.

         21. Participation in other clinical trials in the course of 3 months prior to the
             inclusion in the trial.

         22. Patients, who from the investigator's point of view, will fail to comply with the
             observation requirements of the trial or with the intake regimen of the investigated
             medicines.

         23. Other factors impeding patient's participation in the trial (for example, planned
             business trips or journeys).

         24. Patient is related to the research personnel of the investigative site, who are
             directly involved in the trial or are the immediate relative of the researcher. The
             immediate relative includes husband/wife, parents, children or brothers (or sisters),
             regardless of whether they are natural or adopted.

         25. Patient works for OOO &quot;NPF &quot;Materia Medica Holding&quot; (i.e. is the company's employee,
             temporary contract worker or appointed official responsible for the carrying out the
             research) or the immediate relative.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Municipal budgetary authority &quot;Khimki Central Clinical Hospital&quot;</name>
      <address>
        <city>Moscow region</city>
        <zip>141400</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution of Moscow &quot;Central research institute of gastroenterology&quot; of Department of health care of Moscow</name>
      <address>
        <city>Moscow</city>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Higher Professional Education &quot;Moscow State Medical Academy named after I.M. Sechenov&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nonstate Health Care Institution &quot;Central Clinical Hospital №2 named after N.A. Semashko of Public Limited Company &quot;Russian Railways&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The State Budgetary Institution of Health Care of the Nizhny Novgorod Region &quot;City clinical hospital No. 10 &quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603011</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizhny Novgorod regional State Budgetary Health Institution &quot; Nizhny Novgorod regional Clinical Hospital named after N.A. Semashko &quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Educational Institution of High Professional Training &quot;Rostov State Medical University&quot; of Ministry of Health of Russian Federation, Department of Endocrinology</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Co.Ltd &quot; Diabet Center&quot;</name>
      <address>
        <city>Samara</city>
        <zip>443067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private company &quot;Polyclinic Complex&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Budgetary Health Care Institution &quot;City Polyclinic №6&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191482</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Budgetary Health Care Institution &quot;Saint Venerable Martyr Elizaveta Municipal Hospital&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Educational Institution of High Professional Training &quot;St. Petersburg State Medical University named after academician I.P. Pavlov&quot; of Ministry of Health of Russian Federation, Therapy Faculty Board</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg Sate Budgetary Institution &quot;Consultative-Diagnostic Polyclinic №1 of Coastal Area&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197183</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Independent Health Care Institution of Voronezh Region &quot;Voronezh Regional Clinical Consultative-Diagnostic Center&quot;</name>
      <address>
        <city>Voronezh</city>
        <zip>394018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Health Care Institution of Yaroslavl Region &quot;Regional Сlinical Hospital&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 27, 2013</study_first_submitted>
  <study_first_submitted_qc>May 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2013</study_first_posted>
  <results_first_submitted>November 7, 2017</results_first_submitted>
  <results_first_submitted_qc>November 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 4, 2019</results_first_posted>
  <last_update_submitted>May 15, 2019</last_update_submitted>
  <last_update_submitted_qc>May 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Combined treatment of patients with type I diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study enrolled patients using intensive insulin regimen (Short-acting and Long-acting human insulins) with type 1 diabetes who were not meeting glycemic control (HbA1c&gt;7.0%). Eligible patients were assessed by endocrinologists. The study was performed in 15 medical institutions in Russia from May 2013 to October 2015.</recruitment_details>
      <pre_assignment_details>Selection procedures were carried out after participant enrollment to determine whether the patient could participate in the study in accordance with the inclusion/exclusion criteria.
Of the 200 patients enrolled, 49 did not meet inclusion criteria after screening procedures, they were not randomized</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Subetta</title>
          <description>Short-acting and Long-acting human insulins + Subetta (1 tablet 4 times a day). Subetta: oral administration, per 1 intake – 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Subetta: Efficacy and Safety of Subetta in the combined treatment of patients with type I diabetes mellitus</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Short-acting and Long-acting human insulins + Placebo (1 tablet 4 times a day). Placebo: oral administration, per 1 intake – 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Do not meet inclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention-to-Treat set</population>
      <group_list>
        <group group_id="B1">
          <title>Subetta</title>
          <description>Short-acting and Long-acting human insulins + Subetta (1 tablet 4 times a day). Subetta: oral administration, per 1 intake – 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Subetta: Efficacy and Safety of Subetta in the combined treatment of patients with type I diabetes mellitus</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Short-acting and Long-acting human insulins + Placebo (1 tablet 4 times a day). Placebo: oral administration, per 1 intake – 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="72"/>
            <count group_id="B3" value="144"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.2" spread="9.6"/>
                    <measurement group_id="B2" value="35.0" spread="10.4"/>
                    <measurement group_id="B3" value="36.1" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77.7" spread="15.2"/>
                    <measurement group_id="B2" value="74.4" spread="13.5"/>
                    <measurement group_id="B3" value="76.0" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in the Mean Value of HbA1c</title>
        <description>The HbA1C test was performed using a method that is certified by the National Glycohemoglobin Standardization Program (NGSP) (www.ngsp.org) and standardized or traceable to the Diabetes Control and Complications Trial (DCCT) reference assay.</description>
        <time_frame>baseline and 12, 24 and 36 weeks of the treatment</time_frame>
        <population>Intention-to-Treat set</population>
        <group_list>
          <group group_id="O1">
            <title>Subetta</title>
            <description>Short-acting and Long-acting human insulins + Subetta (1 tablet 4 times a day). Subetta: oral administration, per 1 intake – 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Subetta: Efficacy and Safety of Subetta in the combined treatment of patients with type I diabetes mellitus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Short-acting and Long-acting human insulins + Placebo (1 tablet 4 times a day). Placebo: oral administration, per 1 intake – 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Mean Value of HbA1c</title>
          <description>The HbA1C test was performed using a method that is certified by the National Glycohemoglobin Standardization Program (NGSP) (www.ngsp.org) and standardized or traceable to the Diabetes Control and Complications Trial (DCCT) reference assay.</description>
          <population>Intention-to-Treat set</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="0.91"/>
                    <measurement group_id="O2" value="-0.49" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.94"/>
                    <measurement group_id="O2" value="-0.27" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.99"/>
                    <measurement group_id="O2" value="-0.20" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>The p-value associated with &quot;treatment&quot; factor of changes from baseline to Week 12, 24 and 36 endpoint between Subetta and Placebo treatment groups. Model includes treatment, visit and treatment*visit interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Plasma Glucose (Based on the Data of Biochemical Analysis)</title>
        <time_frame>baseline and 4, 12, 24 and 36 weeks of the treatment</time_frame>
        <population>Intention-to-Treat set</population>
        <group_list>
          <group group_id="O1">
            <title>Subetta</title>
            <description>Short-acting and Long-acting human insulins + Subetta (1 tablet 4 times a day). Subetta: oral administration, per 1 intake – 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Subetta: Efficacy and Safety of Subetta in the combined treatment of patients with type I diabetes mellitus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Short-acting and Long-acting human insulins + Placebo (1 tablet 4 times a day). Placebo: oral administration, per 1 intake – 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose (Based on the Data of Biochemical Analysis)</title>
          <population>Intention-to-Treat set</population>
          <units>mmol / l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="5.1"/>
                    <measurement group_id="O2" value="0.3" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="4.8"/>
                    <measurement group_id="O2" value="0.8" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="4.9"/>
                    <measurement group_id="O2" value="0.7" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="4.8"/>
                    <measurement group_id="O2" value="1.1" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0432</p_value>
            <p_value_desc>The p-value associated with &quot;treatment&quot; factor of changes from baseline to Week 4, 12, 24 and 36 endpoint between Subetta and Placebo treatment groups. Model includes treatment, visit and treatment*visit interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Average Daily Blood Glucose From a 7-point Patient Self-monitoring of Blood Glucose (SMBG)</title>
        <description>A 7-point patient self-monitoring of blood glucose (SMBG):
three measurements of blood glucose before the meal; three measurements of postprandial blood glucose (1-2 h after the start of the meal) and one measurement at 3:00 a.m.</description>
        <time_frame>baseline and 4, 8, 12, 18, 24, 30 and 36 weeks of the treatment</time_frame>
        <population>Intention-to-Treat. 2 patients (1 in Subetta group and 1 in Placebo group) was excluded from the analysis due to lake of diaries</population>
        <group_list>
          <group group_id="O1">
            <title>Subetta</title>
            <description>Short-acting and Long-acting human insulins + Subetta (1 tablet 4 times a day). Subetta: oral administration, per 1 intake – 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Subetta: Efficacy and Safety of Subetta in the combined treatment of patients with type I diabetes mellitus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Short-acting and Long-acting human insulins + Placebo (1 tablet 4 times a day). Placebo: oral administration, per 1 intake – 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average Daily Blood Glucose From a 7-point Patient Self-monitoring of Blood Glucose (SMBG)</title>
          <description>A 7-point patient self-monitoring of blood glucose (SMBG):
three measurements of blood glucose before the meal; three measurements of postprandial blood glucose (1-2 h after the start of the meal) and one measurement at 3:00 a.m.</description>
          <population>Intention-to-Treat. 2 patients (1 in Subetta group and 1 in Placebo group) was excluded from the analysis due to lake of diaries</population>
          <units>mmol / l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.4"/>
                    <measurement group_id="O2" value="0.1" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.7"/>
                    <measurement group_id="O2" value="-0.1" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.6"/>
                    <measurement group_id="O2" value="-0.2" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="2.2"/>
                    <measurement group_id="O2" value="-0.1" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.7"/>
                    <measurement group_id="O2" value="0.0" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.8"/>
                    <measurement group_id="O2" value="-0.1" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.9"/>
                    <measurement group_id="O2" value="0.0" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7344</p_value>
            <p_value_desc>The p-value associated with &quot;treatment&quot; factor of changes from baseline to Week 4, 8, 12, 18, 24, 30 and 36 endpoint between Subetta and Placebo treatment groups. Model includes treatment, visit and treatment*visit interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Lipids (Concentrations of Plasma Total Cholesterol, HDL Cholesterol, LDL Cholesterol and Triglycerides)</title>
        <description>Blood samples (for measurement of fasting plasma glucose, concentrations of plasma total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides) are taken under standard conditions: after night break in food taking (at least 12 hours) and prior to administering of insulin morning dose (prandial), prior to any morning medicines intake (including the study drug and permitted concomitant therapy).</description>
        <time_frame>baseline and 12, 24 and 36 weeks of the treatment</time_frame>
        <population>Intention-to-Treat set</population>
        <group_list>
          <group group_id="O1">
            <title>Subetta</title>
            <description>Short-acting and Long-acting human insulins + Subetta (1 tablet 4 times a day). Subetta: oral administration, per 1 intake – 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Subetta: Efficacy and Safety of Subetta in the combined treatment of patients with type I diabetes mellitus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Short-acting and Long-acting human insulins + Placebo (1 tablet 4 times a day). Placebo: oral administration, per 1 intake – 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Lipids (Concentrations of Plasma Total Cholesterol, HDL Cholesterol, LDL Cholesterol and Triglycerides)</title>
          <description>Blood samples (for measurement of fasting plasma glucose, concentrations of plasma total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides) are taken under standard conditions: after night break in food taking (at least 12 hours) and prior to administering of insulin morning dose (prandial), prior to any morning medicines intake (including the study drug and permitted concomitant therapy).</description>
          <population>Intention-to-Treat set</population>
          <units>mmol / l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total cholesterol (12 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.0"/>
                    <measurement group_id="O2" value="0.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total cholesterol (24 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.1"/>
                    <measurement group_id="O2" value="0.4" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total cholesterol (36 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.0"/>
                    <measurement group_id="O2" value="0.3" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol (12 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.3"/>
                    <measurement group_id="O2" value="0.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol (24 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.3"/>
                    <measurement group_id="O2" value="0.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol (36 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.3"/>
                    <measurement group_id="O2" value="0.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL cholesterol (12 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.8"/>
                    <measurement group_id="O2" value="0.2" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL cholesterol (24 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.9"/>
                    <measurement group_id="O2" value="0.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL cholesterol (36 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.8"/>
                    <measurement group_id="O2" value="0.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides (12 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.6"/>
                    <measurement group_id="O2" value="0.1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides (24 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.6"/>
                    <measurement group_id="O2" value="0.0" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides (36 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.6"/>
                    <measurement group_id="O2" value="0.1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of Total cholesterol changes from baseline to Week 12, 24 and 36 endpoint between Subetta and Placebo treatment groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2780</p_value>
            <p_value_desc>The p-value associated with &quot;treatment&quot; factor of changes from baseline to Week 12, 24 and 36 endpoint between Subetta and Placebo treatment groups. Model includes treatment, visit and treatment*visit interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of HDL cholesterol changes from baseline to Week 12, 24 and 36 endpoint between Subetta and Placebo treatment groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8114</p_value>
            <p_value_desc>The p-value associated with &quot;treatment&quot; factor of changes from baseline to Week 12, 24 and 36 endpoint between Subetta and Placebo treatment groups. Model includes treatment, visit and treatment*visit interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of LDL cholesterol changes from baseline to Week 12, 24 and 36 endpoint between Subetta and Placebo treatment groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1619</p_value>
            <p_value_desc>The p-value associated with &quot;treatment&quot; factor of changes from baseline to Week 12, 24 and 36 endpoint between Subetta and Placebo treatment groups. Model includes treatment, visit and treatment*visit interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of Triglycerides changes from baseline to Week 12, 24 and 36 endpoint between Subetta and Placebo treatment groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0764</p_value>
            <p_value_desc>The p-value associated with &quot;treatment&quot; factor of changes from baseline to Week 12, 24 and 36 endpoint between Subetta and Placebo treatment groups. Model includes treatment, visit and treatment*visit interaction.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Dosage of Insulin (Basal, Prandial and Total Daily Dose Insulin Measured in IU)</title>
        <description>Insulin dose should be corrected by a patient on a daily basis taking into consideration data on blood glucose self- monitoring during a day and amount of food carbohydrates. Physician can correct insulin dose based on the same data.</description>
        <time_frame>baseline and 36 weeks of the treatment</time_frame>
        <population>Intention-to-Treat set</population>
        <group_list>
          <group group_id="O1">
            <title>Subetta</title>
            <description>Short-acting and Long-acting human insulins + Subetta (1 tablet 4 times a day). Subetta: oral administration, per 1 intake – 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Subetta: Efficacy and Safety of Subetta in the combined treatment of patients with type I diabetes mellitus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Short-acting and Long-acting human insulins + Placebo (1 tablet 4 times a day). Placebo: oral administration, per 1 intake – 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Dosage of Insulin (Basal, Prandial and Total Daily Dose Insulin Measured in IU)</title>
          <description>Insulin dose should be corrected by a patient on a daily basis taking into consideration data on blood glucose self- monitoring during a day and amount of food carbohydrates. Physician can correct insulin dose based on the same data.</description>
          <population>Intention-to-Treat set</population>
          <units>IU</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basal insulin (36 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="2.4"/>
                    <measurement group_id="O2" value="0.9" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prandial insulin (36 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="6.9"/>
                    <measurement group_id="O2" value="-0.9" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total daily dose insulin (36 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="8.3"/>
                    <measurement group_id="O2" value="0.0" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of basal insulin changes from baseline to Week 36 endpoint between Subetta and Placebo treatment groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3107</p_value>
            <p_value_desc>The p-value associated with comparison of changes from baseline to Week 36 endpoint between Subetta and Placebo treatment groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of prandial insulin changes from baseline to Week 36 endpoint between Subetta and Placebo treatment groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5236</p_value>
            <p_value_desc>The p-value associated with comparison of changes from baseline to Week 36 endpoint between Subetta and Placebo treatment groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of total daily dose insulin changes from baseline to Week 36 endpoint between Subetta and Placebo treatment groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3847</p_value>
            <p_value_desc>The p-value associated with comparison of changes from baseline to Week 36 endpoint between Subetta and Placebo treatment groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Dosage of Total Insulin Measured in IU/kg of Body Weight</title>
        <description>Insulin dose should be corrected by a patient on a daily basis taking into consideration data on blood glucose self- monitoring during a day and amount of food carbohydrates. Physician can correct insulin dose based on the same data.</description>
        <time_frame>baseline and 36 weeks of the treatment</time_frame>
        <population>Intention-to-Treat set</population>
        <group_list>
          <group group_id="O1">
            <title>Subetta</title>
            <description>Standard therapy of type I diabetes mellitus + Subetta (1 tablet 4 times a day).
Subetta: oral administration, per 1 intake – 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Subetta: Efficacy and Safety of Subetta in the combined treatment of patients with type I diabetes mellitus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Standard therapy of type I diabetes mellitus + Placebo (1 tablet 4 times a day).
Placebo: oral administration, per 1 intake – 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Dosage of Total Insulin Measured in IU/kg of Body Weight</title>
          <description>Insulin dose should be corrected by a patient on a daily basis taking into consideration data on blood glucose self- monitoring during a day and amount of food carbohydrates. Physician can correct insulin dose based on the same data.</description>
          <population>Intention-to-Treat set</population>
          <units>IU/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.09"/>
                    <measurement group_id="O2" value="-0.01" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6716</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction of Diabetes Treatment Based on Diabetes Treatment Satisfaction Questionnaire Data</title>
        <description>The Diabetes Treatment Satisfaction Questionnaire allows to assess the degree of satisfaction with treatment for diabetes and its complications - retinopathy and nephropathy, how patients' satisfaction and perceived hyper- and hypoglycemia have changed compared to the initial period (before the treatment).
The Diabetes Treatment Satisfaction Questionnaire contains six items scored on 7-point scales from +3 (equals &quot;very satisfied&quot;) to -3 (equals &quot;very dissatisfied&quot;), with 0 (equals &quot;no change&quot;). These are summed to produce a total Treatment Satisfaction score. Two questions concerning &quot;Perceived Hyperglycaemia&quot; and &quot;Perceived Hypoglycaemia&quot; respectively, are calculated separately. According to these two items, low scores represent good perceived blood glucose control (+3 means &quot;most of the time&quot; of Hyperglycaemia or Hypoglycaemia whereas -3 means &quot;none of the time&quot; of Hyperglycaemia or Hypoglycaemia).</description>
        <time_frame>36 weeks of the treatment</time_frame>
        <population>Intention-to-Treat set. 6 patients (1 in the Subetta group and 5 in the Placebo group) was excluded from the analysis due to lake of questionnaires.</population>
        <group_list>
          <group group_id="O1">
            <title>Subetta</title>
            <description>Short-acting and Long-acting human insulins + Subetta (1 tablet 4 times a day). Subetta: oral administration, per 1 intake – 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Subetta: Efficacy and Safety of Subetta in the combined treatment of patients with type I diabetes mellitus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Short-acting and Long-acting human insulins + Placebo (1 tablet 4 times a day). Placebo: oral administration, per 1 intake – 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction of Diabetes Treatment Based on Diabetes Treatment Satisfaction Questionnaire Data</title>
          <description>The Diabetes Treatment Satisfaction Questionnaire allows to assess the degree of satisfaction with treatment for diabetes and its complications - retinopathy and nephropathy, how patients' satisfaction and perceived hyper- and hypoglycemia have changed compared to the initial period (before the treatment).
The Diabetes Treatment Satisfaction Questionnaire contains six items scored on 7-point scales from +3 (equals &quot;very satisfied&quot;) to -3 (equals &quot;very dissatisfied&quot;), with 0 (equals &quot;no change&quot;). These are summed to produce a total Treatment Satisfaction score. Two questions concerning &quot;Perceived Hyperglycaemia&quot; and &quot;Perceived Hypoglycaemia&quot; respectively, are calculated separately. According to these two items, low scores represent good perceived blood glucose control (+3 means &quot;most of the time&quot; of Hyperglycaemia or Hypoglycaemia whereas -3 means &quot;none of the time&quot; of Hyperglycaemia or Hypoglycaemia).</description>
          <population>Intention-to-Treat set. 6 patients (1 in the Subetta group and 5 in the Placebo group) was excluded from the analysis due to lake of questionnaires.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="6.6"/>
                    <measurement group_id="O2" value="8.4" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.5"/>
                    <measurement group_id="O2" value="-0.6" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.6"/>
                    <measurement group_id="O2" value="-0.6" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of total Treatment Satisfaction score at Week 36 endpoint between Subetta and Placebo treatment groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2484</p_value>
            <p_value_desc>The p-value associated with comparison of Week 36 endpoint between Subetta and Placebo treatment groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of &quot;Perceived Hyperglycaemia&quot; question at Week 36 endpoint between Subetta and Placebo treatment groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7610</p_value>
            <p_value_desc>The p-value associated with comparison of Week 36 endpoint between Subetta and Placebo treatment groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of &quot;Perceived Hypoglycemia&quot; question at Week 36 endpoint between Subetta and Placebo treatment groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3714</p_value>
            <p_value_desc>The p-value associated with comparison of Week 36 endpoint between Subetta and Placebo treatment groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse/Serious adverse events were registered during 36 weeks of therapy and 30 days after the end of therapy.</time_frame>
      <desc>Adverse/Serious adverse events were registered in patients of the Full Analysis Set (n=151, Safety Population)</desc>
      <group_list>
        <group group_id="E1">
          <title>Subetta</title>
          <description>Standard therapy of type I diabetes mellitus + Subetta (1 tablet 4 times a day).
Subetta: oral administration, per 1 intake – 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Subetta: Efficacy and Safety of Subetta in the combined treatment of patients with type I diabetes mellitus</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Standard therapy of type I diabetes mellitus + Placebo (1 tablet 4 times a day).
Placebo: oral administration, per 1 intake – 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Parotid abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture of humerus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Type I diabetes mellitus with ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension arterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Chronic venous insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Varicose veins of lower extremities</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Inflammation of inguinal lymphonodus on the right</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goiter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Subclinical hypothyreoidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bacterial food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <description>exacerbation of chronic gastritis</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Epigastric pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dentalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Increase in body temperature to 38.5 C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Increase in body temperature up to 38.2 С</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic hepatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reactions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Acute respiratory viral infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Acute respiratory disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Acute bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Parodontosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion of the hand</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Increased blood pressure to 150/90 mm Hg, headache, nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Increased body temperature</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fasting hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in the shoulder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Heavy legs</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Leg cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cervicalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vasomotor rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Increased blood pressure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Putilovskiy, MD, PhD, Clinical Research and Medical Information Director</name_or_title>
      <organization>Materia Medica Holding</organization>
      <phone>+74952761571 ext 302</phone>
      <email>PutilovskiyMA@materiamedica.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

